What Pharma CEOs, PEs Want To Move The Innovation Needle In India

Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.

Pharma CEOs, PEs Discuss Key Elements To Catalyse Innovation In India • Source: Shutterstock

Industry heads at a recent conclave discussed some of the key issues weighing on India’s ascent up the innovation value chain including the criticality of a robust domestic market for novel products, an effective reimbursement mechanism and regulatory reform as part of developing the overall ecosystem.

More from Global Vision

More from In Vivo

Only Half Of 2024’s Biggest Launches Belong To Big Pharma

 

Just a handful of big pharma approvals of 2024 are tipped to be multi-billion dollar blockbusters. Even though it is still early days for these drugs, the pull of M&A is looking increasingly strong for big pharma as more smaller firms go it alone.

Taming Dragons: AI Innovation For Blood Cancer Drug Discovery

 
• By 

CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.

Navigating AI In Healthtech With Effective Risk Management

 
• By 

Risk management and the need for back-up systems are fast emerging as themes that users of artificial intelligence tools in health care settings must face up to. Now more comfortable with the technology’s capabilities, health care stakeholders appreciate that there can be two sides to the AI coin.